Specifically, for those with locally advanced NPC (LA NPC), EGFR-targeted agents combined with induction chemotherapy have significantly higher disease-free survival (DFS) rates and fewer side effects. The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.